<\/p>\n\n\n\n
PCOS, or polycystic ovary syndrome, is getting a new title, and it\u2019s a mouthful. As announced by a May 2026 art\u00edculo<\/a> in prestigious medical journal The Lancet<\/em>, PCOS is being renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. Following a three-year transition period, the term \u2018PCOS\u2019 will be permanently replaced with \u2018PMOS\u2019 in international medical research, doctor\u2019s offices, educaci\u00f3n<\/a>, and advocacy efforts. <\/p>\n\n\n\n Here\u2019s why the name change isn\u2019t just a rebrand or glow-up, but a worthwhile, needed acknowledgment that ovarian cysts aren\u2019t the main focus of this long-underdiagnosed condition that affects 170 million worldwide.<\/p>\n\n\n\n Historically, PCOS was considered to be a reproductive problem driven by excess androgens (sex hormones that trigger male characteristics). Internally, women with PCOS were believed to have multiple cysts on the ovaries, hence the \u2018polycystic\u2019 in the name. External characteristics included irregular cycles, anovulation (no ovulation), hair in places it didn\u2019t belong and more consistent with male hair growth patterns (think on the chin or neck and chest) and being overweight or obese. <\/p>\n\n\n\n In recent years, we\u2019ve chronicled multiple shifts in our cultural and medical understanding of PCOS. We\u2019ve known for some time that PCOS doesn\u2019t look the same for everyone, as we noted with our article on \u201cSOP magro<\/a>.\u201d What\u2019s more, it has health implications for other body systems m\u00e1s all\u00e1 de<\/em> the reproductive system, as we covered in our articles on PCOS and memory loss in mid-life<\/a> y PCOS and hearing loss<\/a>. We also spotlighted the increasingly clear connection between PCOS and problemas metab\u00f3licos<\/a> como resistencia a la insulina<\/a>. <\/p>\n\n\n\n The new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), ties all the above threads together, and was developed from the resultados<\/a> of 22,000 survey responses from patients and healthcare professionals, plus the collaboration of dozens of domestic and international medical and advocacy organizations, among them<\/a>: The International PCOS Network – Monash University, NHMRC Centre for Research Excellence in Women\u2019s Health in Reproductive Life (CRE-WHiRL), AE-PCOS (International Androgen Excess and Polycystic Ovary Syndrome Society), and UK patient group Verity). <\/p>\n\n\n\n The name change reflects three key facts. First, ovarian cysts aren\u2019t a main feature of PCOS\/PMOS. Second, PMOS is a chronic condition, not just affecting reproductive-aged women. Thirdly, PMOS isn\u2019t just a reproductive issue. <\/p>\n\n\n\n The name change reflects three key facts. First, ovarian cysts aren\u2019t a main feature of PCOS\/PMOS. Second, PMOS is a chronic condition, not just affecting reproductive-aged women. Thirdly, PMOS isn\u2019t just a reproductive issue. <\/p><\/blockquote><\/figure>\n\n\n\n \u201cWhat we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,\u201d stated Professor Helena Teede<\/a>, the Monash University professor who spearheaded the name change, according to a comunicado de prensa<\/a> from the Endocrine Society. <\/p>\n\n\n\n What was previously believed to be multiple cysts on the ovaries is actually a case of arrested development: clusters of immature follicles that never reached the point of ovulation and look like cysts on imaging. <\/p>\n\n\n\n The name change also acknowledges that PCOS doesn\u2019t strictly affect reproductive-aged women, as we alluded to in our article on the connection between PCOS and cognitive decline later in life, nor does it simply go away over time. As one example, the metabolic impacts of PCOS don\u2019t just end when a woman\u2019s periods stop. <\/p>\n\n\n\n And here\u2019s the kicker, PMOS may not be a strictly mujer <\/em>issue either. Back in September of 2025, Pizarra<\/a> published an article noting that certain PCOS-associated genes in affected women were also noted in their first-degree male relatives. Unlike their female counterparts, these men tended to have too-bajo<\/em> levels of androgens. Furthermore, they didn\u2019t have reproductive issues so much as skin-related (early male-pattern baldness) and metabolic ones, like insulin resistance and obesity. <\/p>\n\n\n\n An April 2026 Stat article<\/a> clarified, \u201cAt present, this condition is diagnosed as PCOS in women; in men, similar features, especially in relatives, reflect shared genetic and metabolic pathways rather than a formally defined syndrome,\u201d quoting Okan B\u00fclent Y\u0131ld\u0131z, a Turkish professor of medicine and endocrinology. Y\u0131ld\u0131z co-authored a widely-cited April 2025 article in Naturaleza<\/em><\/a> exploring how metabolic dysfunction runs in whole families of women with PCOS, and arguing that metabolic issues, not just reproductive problems<\/em>, are key characteristics of PCOS. <\/p>\n\n\n\n En Lancet<\/em> art\u00edculo<\/a> spelled out the potential manifestations of PMOS from the perspective of multiple body systems. Symptoms might be \u201cmetabolic (ie, obesity, dysglycaemia, type 2 diabetes, hypertension, dyslipidaemia, metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, and sleep apnoea), reproductive (ovulatory disturbances, irregular menstrual cycles, infertility, pregnancy complications, and endometrial cancer), psychological (depression, anxiety, poor quality of life, and eating disorders), and dermatological (acne, alopecia, and hirsutism).\u201d\u00a0\u00a0<\/p>\n\n\n\n Symptoms of PMOS might be \u201cmetabolic, reproductive, psychological, and dermatological.\u201d\u00a0\u00a0<\/p><\/blockquote><\/figure>\n\n\n\n The title \u2018Polyendocrine Metabolic Ovarian Syndrome\u2019 represents the multisystem hormonal, metabolic, y<\/em> reproductive effects of this condition. <\/p>\n\n\n\n Social media was already abuzz on May 12, with women\u2019s health advocates and medicina reproductiva reparadora<\/a> practitioners celebrating the news. <\/p>\n\n\n\n En Fundaci\u00f3n Americana contra la Endometriosis<\/a> recognized that many women with endometriosis also experience PCOS and stand to gain from the name change. <\/p>\n\n\n\n Popular double board-certified OB\/GYN and reproductive endocrinologist Dr. Natalie Crawford, MD wrote,<\/a> in part, \u201c…importantly, many patients and advocacy groups pushed for this change because the current name has contributed to years of confusion, delayed diagnosis, and dismissal. A new name won\u2019t fix everything. But it may help move the conversation toward earlier diagnosis, better research, and more comprehensive care.\u201d <\/p>\n\n\n\n Napro-trained OB\/GYN Dr. Naomi Whittaker reshared a Correo electr\u00f3nico:<\/a> from the account Sacred as a Mother, which read, in part, \u201cPolyendocrine Metabolic Ovarian Syndrome has never been a condition of the ovary. But a larger metabolic event using the ovary to communicate. The cystic follicles, insulin resistance, and cyclic dysregulation were delegates for a female living system stuck in an evolutionary mismatch with modern biological antagonism. The ovaries have been downstream the entire time. Wise organs communicating with us, showing us the fire\u2013and we blamed the smoke.\u201d <\/p>\n\n\n\n Whittaker commented, \u201cI\u2019m obsessed with this analysis and update. \ud83d\udd25\ud83d\udd25\ud83d\udd25\ud83d\udd25\ud83d\udd25\ud83d\udd25 every thing. The female organs have been the scapegoats the entire time! ENOUGH with the misogyny!!\u201d\u00a0<\/p>\n\n\n\n Ginny Noce of The Women\u2019s Health RN<\/a> called<\/a> the name change \u201ca step in the right direction\u201d while cautioning against focusing solely on the metabolic aspects of PMOS. She wrote, \u201cThere are seven critical drivers in addition to insulin resistance that I address in every PCOS\/PMOS case in my practice.\u201d Among them are inflammation, oxidative stress, gut health, nutrient deficiencies. In her post, Noce also questioned whether overemphasizing the metabolic dysfunction part of PCOS\/PMOS could \u201cpotentially just lead to more Metformin and GLP-1s?\u201d She summed up, \u201cWomen with PCOS\/PMOS deserve a full-scope investigation and care plan\u2014not just a new drug target.\u201d\u00a0\u00a0<\/p>\n\n\n\n The name change from PCOS to PMOS isn\u2019t some slick marketing tactic (after all, \u2018polyendocrine metabolic ovarian syndrome\u2019 doesn\u2019t really roll off the tongue). It\u2019s the result of years of thoughtful collaboration between healthcare professionals and thousands of women\u2019s lived experience. PCOS, now PMOS, isn\u2019t ultimately about ovarian cysts, nor is it a strictly reproductive issue. <\/p>\n\n\n\nHow our understanding of PCOS has evolved in recent years <\/span><\/h2>\n\n\n\n
What the name change signifies<\/span><\/h2>\n\n\n\n
Ovarian cysts aren\u2019t a main feature of PCOS\/PMOS<\/span><\/h3>\n\n\n\n
PMOS is a chronic condition\u2026<\/span><\/h3>\n\n\n\n
\u2026And it might not be just for women<\/span><\/h3>\n\n\n\n
PMOS is a metabolic, hormonal, mental health, skin, y<\/em> reproductive condition<\/span><\/h3>\n\n\n\n
RRM experts and women\u2019s health advocates are thrilled with the name change<\/span><\/h2>\n\n\n\n
An OB\/GYN and reproductive endocrinologist’s take<\/span><\/h3>\n\n\n\n
An OB\/GYN and NaPro-trained surgeon’s take<\/span><\/h3>\n\n\n\n
A functional nutritionist’s take<\/span><\/h3>\n\n\n\n
The bottom line on the PCOS rebrand<\/span><\/h2>\n\n\n\n